Overexpression of miR‑518b in non‑small cell lung cancer serves as a biomarker and facilitates tumor cell proliferation, migration and invasion

Zhang,Xinfang; Hu,Ying; Gong,Cuixue; Zhang,Chunjie

doi:10.3892/ol.2020.11667

Overexpression of miR‑518b in non‑small cell lung cancer serves as a biomarker and facilitates tumor cell proliferation, migration and invasion

Authors:
- Xinfang Zhang
- Ying Hu
- Cuixue Gong
- Chunjie Zhang
View Affiliations

Affiliations: Clinical Laboratory, Qilu Hospital Huantai Branch, Zibo, Shandong 256400, P.R. China, Department of Blood Transfusion, Qilu Hospital Huantai Branch, Zibo, Shandong 256400, P.R. China, Outpatient Department, Zibo Central Hospital, Zibo, Shandong 255000, P.R. China, Clinical Laboratory, Zibo Central Hospital, Zibo, Shandong 255000, P.R. China
Published online on: May 22, 2020 https://doi.org/10.3892/ol.2020.11667
Pages: 1213-1220
Copyright: © Zhang et al. This is an open access article distributed under the terms of Creative Commons Attribution License.

Metrics: Total Views: 0 (Spandidos Publications: | PMC Statistics: )

Metrics: Total PDF Downloads: 0 (Spandidos Publications: | PMC Statistics: )

Cited By (CrossRef): 0 citations Loading Articles...

Abstract

Several microRNAs (miRNA/miR) have been reported to serve critical roles in tumorigenesis. The present study aimed to investigate miR‑518b expression in non‑small cell lung cancer (NSCLC), and determine its clinical significance and biological function in this malignancy. Reverse transcription‑quantitative PCR was performed to assess miR‑518b expression in NSCLC. The diagnostic value of miR‑518b was determined via a receiver operating characteristic curve, while its prognostic value was assessed using the Kaplan‑Meier method. Gain‑ and loss‑of‑function experiments were performed to determine the functional role of miR‑518b in NSCLC progression. The results demonstrated that miR‑518b expression was upregulated in NSCLC serum, tissues and cell lines compared with the corresponding normal controls. Furthermore, high miR‑518b expression was significantly associated with larger tumor size, lymph node metastasis and advanced TNM stage, as well as poor overall survival in patients with NSCLC. Serum miR‑518b expression was identified as a candidate diagnostic biomarker for NSCLC, with sensitivity of 88.1% and specificity of 81.7%. Furthermore, the cell experiments indicated that NSCLC cell proliferation, migration and invasion were enhanced following overexpression of miR‑518b; however, these effects were reversed following miR‑518b knockdown. Taken together, the results of the present study suggest that elevated miR‑518b expression in NSCLC serves a potential oncogenic role by facilitating tumor cell proliferation, migration and invasion, and thus may serve as a candidate diagnostic and prognostic biomarker.

View Figures

View References

1	Torre LA, Siegel RL and Jemal A: Lung cancer statistics. Adv Exp Med Biol. 893:1–19. 2016. View Article : Google Scholar : PubMed/NCBI
2	Torre LA, Bray F, Siegel RL, Ferlay J, Lortet-Tieulent J and Jemal A: Global cancer statistics, 2012. CA Cancer J Clin. 65:87–108. 2015. View Article : Google Scholar : PubMed/NCBI
3	Akhurst T: Staging of Non-Small-Cell Lung Cancer. PET Clin. 13:1–10. 2018. View Article : Google Scholar : PubMed/NCBI
4	Valentino F, Borra G, Allione P and Rossi L: Emerging targets in advanced non-small-cell lung cancer. Future Oncol. 14:61–72. 2018. View Article : Google Scholar : PubMed/NCBI
5	Hirsch FR, Scagliotti GV, Mulshine JL, Kwon R, Curran WJ Jr..Wu YL and Paz-Ares L: Lung cancer: Current therapies and new targeted treatments. Lancet. 389:299–311. 2017. View Article : Google Scholar : PubMed/NCBI
6	Heist RS and Engelman JA: SnapShot: Non-small cell lung cancer. Cancer Cell. 21:448.e22012. View Article : Google Scholar : PubMed/NCBI
7	Zhang X, Zheng Q, Wang C, Zhou H, Jiang G, Miao Y, Zhang Y, Liu Y, Li Q, Qiu X and Wang E: CCDC106 promotes non-small cell lung cancer cell proliferation. Oncotarget. 8:26662–26670. 2017. View Article : Google Scholar : PubMed/NCBI
8	Zhou X, Xu X, Gao C and Cui Y: XIST promote the proliferation and migration of non-small cell lung cancer cells via sponging miR-16 and regulating CDK8 expression. Am J Transl Res. 11:6196–6206. 2019.PubMed/NCBI
9	Peng H, Pan X, Su Q, Zhu LS and Ma GD: MiR-372-3p promotes tumor progression by targeting LATS2 in colorectal cancer. Eur Rev Med Pharmacol Sci. 23:8332–8344. 2019.PubMed/NCBI
10	Shi C, Yang Y, Zhang L, Yu J, Qin S, Xu H and Gao Y: MiR-200a-3p promoted the malignant behaviors of ovarian cancer cells through regulating PCDH9. Onco Targets Ther. 12:8329–8338. 2019. View Article : Google Scholar : PubMed/NCBI
11	Zhang Z, Zhang L, Wang B, Wei R, Wang Y, Wan J, Zhang C, Zhao L, Zhu X, Zhang Y, et al: MiR-337-3p suppresses proliferation of epithelial ovarian cancer by targeting PIK3CA and PIK3CB. Cancer Lett. 469:54–67. 2019. View Article : Google Scholar : PubMed/NCBI
12	Chen Y, Gao DY and Huang L: In vivo delivery of miRNAs for cancer therapy: Challenges and strategies. Adv Drug Deliv Rev. 81:128–141. 2015. View Article : Google Scholar : PubMed/NCBI
13	Xu X, Ban Y, Zhao Z, Pan Q and Zou J: MicroRNA-1298-3p inhibits proliferation and invasion of glioma cells by downregulating Nidogen-1. Aging (Albany NY). 12:2020.(Epub ahead of print).
14	Wu X: Expressions of miR-21 and miR-210 in breast cancer and their predictive values for prognosis. Iran J Public Health. 49:21–29. 2020.PubMed/NCBI
15	Wang J, Shu H and Guo S: MiR-646 suppresses proliferation and metastasis of non-small cell lung cancer by repressing FGF2 and CCND2. Cancer Med. Apr 29–2020.(Epub ahead of print). View Article : Google Scholar
16	Qiu Z, Li H, Wang J and Sun C: miR-146a and miR-146b in the diagnosis and prognosis of papillary thyroid carcinoma. Oncol Rep. 38:2735–2740. 2017. View Article : Google Scholar : PubMed/NCBI
17	Yuan Z, Baker K, Redman MW, Wang L, Adams SV, Yu M, Dickinson B, Makar K, Ulrich N, Bohm J, et al: Dynamic plasma microRNAs are biomarkers for prognosis and early detection of recurrence in colorectal cancer. Br J Cancer. 117:1202–1210. 2017. View Article : Google Scholar : PubMed/NCBI
18	Bie LY, Li N, Deng WY, Lu XY, Guo P and Luo SX: Serum miR-191 and miR-425 as diagnostic and prognostic markers of advanced gastric cancer can predict the sensitivity of FOLFOX chemotherapy regimen. Onco Targets Ther. 13:1705–1715. 2020. View Article : Google Scholar : PubMed/NCBI
19	Xia J, Li D, Zhu X, Xia W, Qi Z, Li G and Xu Q: Upregulated miR-665 expression independently predicts poor prognosis of lung cancer and facilitates tumor cell proliferation, migration and invasion. Oncol Lett. 19:3578–3586. 2020.PubMed/NCBI
20	Xing Z, Li S, Liu Z, Zhang C and Bai Z: CTCF-induced upregulation of HOXA11-AS facilitates cell proliferation and migration by targeting miR-518b/ACTN4 axis in prostate cancer. Prostate. 80:388–398. 2020. View Article : Google Scholar : PubMed/NCBI
21	Zheng J, Sadot E, Vigidal JA, Klimstra DS, Balachandran VP, Kingham TP, Allen PJ, D'Angelica MI, DeMatteo RP, Jarnagin WR and Ventura A: Characterization of hepatocellular adenoma and carcinoma using microRNA profiling and targeted gene sequencing. PLoS One. 13:e02007762018. View Article : Google Scholar : PubMed/NCBI
22	Wang W, Zhao LJ, Tan YX, Ren H and Qi ZT: MiR-138 induces cell cycle arrest by targeting cyclin D3 in hepatocellular carcinoma. Carcinogenesis. 33:1113–1120. 2012. View Article : Google Scholar : PubMed/NCBI
23	Liang W, Li X, Li Y, Li C, Gao B, Gan H, Li S, Shen J, Kang J, Ding S, Lin X and Liao L: Gallic acid induces apoptosis and inhibits cell migration by upregulating miR-518b in SW1353 human chondrosarcoma cells. Int J Oncol. 44:91–98. 2014. View Article : Google Scholar : PubMed/NCBI
24	Zhang M, Zhou S, Zhang L, Zhang J, Cai H, Zhu J, Huang C and Wang J: miR-518b is down-regulated, and involved in cell proliferation and invasion by targeting Rap1b in esophageal squamous cell carcinoma. FEBS Lett. 586:3508–3521. 2012. View Article : Google Scholar : PubMed/NCBI
25	Xu C, Zheng Y, Lian D, Ye S, Yang J and Zeng Z: Analysis of microRNA expression profile identifies novel biomarkers for non-small cell lung cancer. Tumori. 101:104–110. 2015. View Article : Google Scholar : PubMed/NCBI
26	Singletary SE, Allred C, Ashley P, Bassett LW, Berry D, Bland KI, Borgen PI, Clark GM, Edge SB, Hayes DF, et al: Staging system for breast cancer: Revisions for the 6th edition of the AJCC cancer staging manual. Surg Clin North Am. 83:803–819. 2003. View Article : Google Scholar : PubMed/NCBI
27	Livak KJ and Schmittgen TD: Analysis of relative gene expression data using real-time quantitative PCR and the 2(-Delta Delta C(T)) Method. Methods. 25:402–408. 2001. View Article : Google Scholar : PubMed/NCBI
28	Chu GCW, Lazare K and Sullivan F: Serum and blood based biomarkers for lung cancer screening: A systematic review. BMC Cancer. 18:1812018. View Article : Google Scholar : PubMed/NCBI
29	Shin VY and Chu KM: MiRNA as potential biomarkers and therapeutic targets for gastric cancer. World J Gastroenterol. 20:10432–10439. 2014. View Article : Google Scholar : PubMed/NCBI
30	Adhami M, Haghdoost AA, Sadeghi B and Malekpour Afshar R: Candidate miRNAs in human breast cancer biomarkers: A systematic review. Breast Cancer. 25:198–205. 2018. View Article : Google Scholar : PubMed/NCBI
31	Hashemi ZS, Khalili S, Forouzandeh Moghadam M and Sadroddiny E: Lung cancer and miRNAs: A possible remedy for anti-metastatic, therapeutic and diagnostic applications. Expert Rev Respir Med. 11:147–157. 2017. View Article : Google Scholar : PubMed/NCBI
32	Yang X and Wang P: MiR-188-5p and MiR-141-3p influence prognosis of bladder cancer and promote bladder cancer synergistically. Pathol Res Pract. 215:1525982019. View Article : Google Scholar : PubMed/NCBI
33	Ning S, Liu H, Gao B, Wei W, Yang A, Li J and Zhang L: miR-155, miR-96 and miR-99a as potential diagnostic and prognostic tools for the clinical management of hepatocellular carcinoma. Oncol Lett. 18:3381–3387. 2019.PubMed/NCBI
34	Du W, Tang H, Lei Z, Zhu J, Zeng Y, Liu Z and Huang JA: miR-335-5p inhibits TGF-beta1-induced epithelial-mesenchymal transition in non-small cell lung cancer via ROCK1. Respir Res. 20:2252019. View Article : Google Scholar : PubMed/NCBI
35	Li Q, Wu X, Guo L, Shi J and Li J: MicroRNA-7-5p induces cell growth inhibition, cell cycle arrest and apoptosis by targeting PAK2 in non-small cell lung cancer. FEBS Open Bio. 9:1983–1993. 2019. View Article : Google Scholar : PubMed/NCBI
36	Ma X, Zhou J, Mo H and Ying Y: Association of miR-100 expression with clinicopathological features and prognosis of patients with lung cancer. Oncol Lett. 18:1318–1322. 2019.PubMed/NCBI
37	Mott TF: Lung Cancer: Management. FP Essent. 464:27–30. 2018.PubMed/NCBI
38	Yang X, Zhang Q, Zhang M, Su W, Wang Z, Li Y, Zhang J, Beer DG, Yang S and Chen G: Serum microRNA signature is capable of early diagnosis for non-small cell lung cancer. Int J Biol Sci. 15:1712–1722. 2019. View Article : Google Scholar : PubMed/NCBI
39	Zhuang Z, Sun C and Gong H: High serum miR-484 expression is associated with the diagnosis and prognosis of patients with non-small cell lung cancer. Exp Ther Med. 18:4095–4102. 2019.PubMed/NCBI
40	Zhang YL, Zhang ZL, Zhu XB, Xu L, Lu P, Xu M, Liu WJ, Zhang XY, Yao HM and Ye XW: Low plasma miR-25 expression is a favorite prognosis factor in non-small cell lung cancer. Eur Rev Med Pharmacol Sci. 23:5251–5259. 2019.PubMed/NCBI
41	Li Y, Cui X, Li Y, Zhang T and Li S: Upregulated expression of miR-421 is associated with poor prognosis in non-small-cell lung cancer. Cancer Manag Res. 10:2627–2633. 2018. View Article : Google Scholar : PubMed/NCBI
42	Hu C, Peng J, Lv L, Wang X, Zhou Y, Huo J and Liu D: miR-196a regulates the proliferation, invasion and migration of esophageal squamous carcinoma cells by targeting ANXA1. Oncol Lett. 17:5201–5209. 2019.PubMed/NCBI
43	Arabsorkhi Z, Gharib E, Yaghmoorian Khojini J, Farhadieh ME, Nazemalhosseini-Mojarad E and Zali MR: miR-298 plays a pivotal role in colon cancer invasiveness by targeting PTEN. J Cell Physiol. 235:4335–4350. 2019. View Article : Google Scholar : PubMed/NCBI
44	Han X, Du C, Chen Y, Zhong X, Wang F, Wang J, Liu C, Li M, Chen S and Li B: Overexpression of miR-939-3p predicts poor prognosis and promotes progression in lung cancer. Cancer Biomark. 25:325–332. 2019. View Article : Google Scholar : PubMed/NCBI
45	Huang T, Wang G, Yang L, Peng B, Wen Y, Ding G and Wang Z: MiR-186 inhibits proliferation, migration, and invasion of non-small cell lung cancer cells by downregulating Yin Yang 1. Cancer Biomark. 21:221–228. 2017. View Article : Google Scholar : PubMed/NCBI
46	Tang X, Ding Y, Wang X, Wang X, Zhao L and Bi H: miR-650 promotes non-small cell lung cancer cell proliferation and invasion by targeting ING4 through Wnt-1/β-catenin pathway. Oncol Lett. 18:4621–4628. 2019.PubMed/NCBI
47	Tian G, Wang SW, Song M, Hu YF, Cao XN and Ge JW: MicroRNA-16 inhibits the proliferation, migration and invasion of non-small cell lung carcinoma cells by down-regulating matrix metalloproteinase-19 expression. Eur Rev Med Pharmacol Sci. 23:5260–5269. 2019.PubMed/NCBI
48	Kushwaha R, Thodima V, Tomishima MJ, Bosl GJ and Chaganti RS: miR-18b and miR-518b Target FOXN1 during epithelial lineage differentiation in pluripotent cells. Stem Cells Dev. 23:1149–1156. 2014. View Article : Google Scholar : PubMed/NCBI
49	Ji X, Ji Y, Wang W and Xu X: Forkhead box N1 inhibits the progression of non-small cell lung cancer and serves as a tumor suppressor. Oncol Lett. 15:7221–7230. 2018.PubMed/NCBI